On this week’s Biotech Hangout, hosts Daphne Zohar, Tim Opler, Dawn Bell, Ethan Perlstein and Eric Schmidt discuss the latest in biotech news, including the overall performance of IPOs this year, including Metagenomi’s IPO this week and what it means for the IPO window. The hosts also debate the value of tracking 13Fs as an investment strategy, M&A news including Gilead’s $4.3B acquisition of CymaBay, plus offerings and some related data for Larimar ($150M offering and Phase 2 data), PRIME Medicine ($140M offering), Sana ($165M offering), Crispr ($250M offering) and KalVista ($160M offering and Phase 3 data). The group also commented on news from two companies – Merrimack Pharmaceuticals and LianBio – who will both be winding down and returning the capital to shareholders. Additional topics of discussion include CSL’s Phase 3 trial failure to hit primary endpoint, Alnylam’s decision to change its statistical analysis plan on Helios-B, and private financing mega rounds that drew attention this year, including BioAge Labs’s $170M Series D and Latigo’s $135M Series A financing. This episode aired on February 16, 2024.